

**REMARKS/ARGUMENTS**

Claims 1, 4, and 10 has been amended. Support for these amendments can be found throughout the specification and in the original claims, as described below. Specifically, the term "corresponding" has been amended to "complementary." Support for these amendments can be found in the specification on page 6, line 13. Additional support for the amendment to claim 1 can be found in the specification on page 6, lines 6-7. Therefore, no new matter has been added by way of claim amendment. Entry of these amendments to the claims of the above-referenced application is respectfully requested. Claims 1-12 are now pending in the application. Reexamination and reconsideration of the claims is respectfully requested in view of the following remarks. The Examiner's comments in the Office Action are addressed below in the order set forth therein.

**The Rejection of the Claims Under the Judicially Created Doctrine of Obviousness-Type Double Patenting Should Be Withdrawn**

Claims 1-12 are rejected under the judicially created doctrine of obviousness-type double Patenting. This rejection is respectfully traversed by filing of a terminal disclaimer attached herewith.

**The Rejection of the Claims Under 35 U.S.C. §102(b) Should Be Withdrawn**

Claim 1 is rejected under 35 U.S.C. §102(b) in view of Hirashima *et al.* This rejection is respectfully traversed.

Claim 1 has been amended to clarify that the flanking sequence has at least a portion or portions of a target gene. Thus, the operative flanking sequence cannot be endogenous to the mRNA encoding the protein of interest as in Hirashimi *et al.* Support for this amendment resides in the specification on page 6, lines 6-7.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required

therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,




C. Allen Black  
Registration No. 53,835

**Customer No. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number ER 484431842US  
Date of Deposit May 27, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:  
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Pamela Lockley